Overview

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and PrednisoneT-CHP in Previously Untreated Patients With CD20-positive DLBCL

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

Summary

This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule. Patients with previously untreated patients with CD20-positive DLBCL were selected to evaluate the safety, tolerance (DLT, MTD), pharmacokinetics, and anti-tumor activity of TRS005 in combination with standard doses of cyclophosphamide, doxorubicin, and prednisoneT-CHP by intravenous drip every 3 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Zhejiang Teruisi Pharmaceutical Inc.

Treatments:

Cyclophosphamide
Doxorubicin
Prednisolone